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Summary
 
p73 has been recently identified as a new structural and functional homologue of the transcrip-
 
tion factor p53. It is expressed in either a full-length form, 
 
a
 
, or a shorter 
 
b
 
 mRNA variant,
with exon 13 spliced out. Here we report the identification and functional characterization of
two new p73 splicing variants, 
 
g
 
 (splicing out exon 11) and 
 
d
 
 (splicing out exons 11, 12, and
13). Both 
 
g
 
 and 
 
d
 
 p73 variants are expressed in human peripheral blood lymphocytes, primary
keratinocytes, and different tumor cell lines, including neuroblastoma, glioblastoma, mela-
noma, hepatoma, and leukemia. The expression pattern of the four p73 splicing variants differs
in both primary cells of different lineage and established cell lines even within the same type of
tumor. A two-hybrid assay was used to characterize the homodimeric and heterodimeric inter-
actions between the p73 variants, and showed that neither p73
 
g
 
 nor p73
 
d
 
 interact with p53,
whereas p73
 
g
 
 showed strong interactions with all p73 isoforms, and p73
 
d
 
 binds efficiently
p73
 
a
 
 and p73
 
g
 
 but only weakly p73
 
b
 
. At the functional level, p73
 
g
 
 is significantly less efficient
 
in activating transcription of the p21
 
Waf1/Cip1
 
 promoter than p53 or p73
 
b
 
, whereas the effect of
p73
 
d
 
 is intermediate and comparable to that of p73
 
a
 
. The ability of the different p73 variants
to affect cell growth in p53 null osteosarcoma SAOS-2 cells correlates with their transcriptional
activity on the p21
 
Waf1/Cip1
 
 promoter: p73
 
b
 
 is the most efficient in inhibiting colony formation,
whereas p73
 
g
 
 is almost ineffective. Our results suggest that p73 isoforms may be differentially
regulated, with four different isoforms capable of interacting among themselves and with p53.
The relative expression level of each splice variant may modulate p73 transcriptional and
growth suppression activities by affecting heterodimer formation.
Key words: p73 • p53 • differentiation • apoptosis • cancer
 
T
 
he p53 tumor suppressor gene (1, 2) is the most fre-
quent target for genetic alterations in human cancers
(3, 4). Attempts to find p53-related genes by low strin-
gency hybridization or by degenerate PCR techniques, in
analogy to the pRb family of tumor suppressors, have re-
peatedly failed. A new gene, p73, has recently been identi-
fied that encodes a protein with structural and functional
homology to p53 (5). The biological activities of the p53
protein that have been implicated in tumor suppression in-
clude growth arrest at both the G
 
1
 
/S and the G
 
2
 
/M transi-
tions of the cell cycle (2, 6), and induction of apoptosis (7).
To exert most if not all of its functions, p53 acts as a tran-
scriptional activator on numerous genes that contain spe-
cific DNA-binding sequences on their promoter, such as
p21
 
Waf1/Cip1
 
 (8, 9) and gadd45 (10), or as a transcription re-
pressor on genes that do not contain such sequences, prob-
ably by sequestering transcription factors (11, 12). Similar
to p53, p73 can activate transcription of p21
 
Waf1/Cip1
 
, a gene
involved in cell growth arrest, and can induce apoptosis
when overexpressed (5, 13). p73 gene maps to the short
arm of chromosome 1 in a region (1p36.33) that is fre-
quently deleted in neuroblastomas (14, 15), suggesting that
it may play a role in the development of these tumors.
However, allelic loss in lung cancers does not show imbal-
ance of expression or mutations of the remaining allele
(16), and p73 mutations do not appear to be frequent in
prostate carcinoma (17).
Despite its structural and functional similarities to p53,
p73 is not induced by DNA damaging agents (UV irradia-
tion or actinomycin D) known to activate p53, suggesting
that p73 may have different functions and may be involved
in the cellular response to different stimuli (5, 18). p73,
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which is capable of interacting with p53 in a yeast two-
hybrid system (5), may also modulate the function of the
latter. The full-length protein, p73
 
a
 
, has been shown to be
expressed in parallel with a shorter splice variant, p73
 
b
 
, in
which the splicing of exon 13 results in a much shorter
COOH terminus (5). Here we identify and characterize
the functional properties of two new splice variants of the
p73 gene, called p73
 
g
 
 and p73
 
d
 
, differentially expressed
both in normal human cells and in tumor cell lines.
 
Materials and Methods
 
p73 Cloning.
 
Reverse transcription (RT)-PCR for all p73
variants used the following primers derived from the published
p73 cDNA sequence (sequence data available from EMBL/Gen-
Bank/DDBJ under accession no. Y11416): 5
 
9
 
-TTCTGCAGGT-
GACTCAGGCTG-3
 
9
 
 for RT; and 5
 
9
 
-TTAGCGCTATGGC-
CCAGTCCACCGCC-3
 
9
 
 (sense primer containing an in-frame
NheI site) and 5
 
9
 
-CGAGGCCTCAGTGGATCTGC-3
 
9
 
 (anti-
sense primer) for PCR amplification. cDNA synthesis was per-
formed using 1 
 
m
 
g of total RNA, extracted from the SH-Sy5y
cell line using TRIZOL (Life Technologies, Inc., Gaithersburg,
MD), in 20 
 
m
 
l of reaction buffer containing 50 mM Tris-HCl
(pH 8.3), 75 mM KCl, 3 mM MgCl
 
2
 
,
 
 
 
10 mM dithiothreitol,
dNTPs 0.5 mM each, primers 1 
 
m
 
M each, and 200 U of Super-
Script RNaseH
 
2
 
 reverse transcriptase (GIBCO BRL, Gaithers-
burg, MD), for 1 h at 37
 
8
 
C. The PCR reaction was performed
in 50 
 
m
 
l of reaction buffer containing 4 
 
m
 
l of the RT product,
50 mM KCl, 10 mM Tris-HCl (pH 9.0 at 25
 
8
 
C), 0.1% Triton
X-100, 1.5 mM MgCl
 
2
 
, dNTPs 0.2 mM each, primers 0.4 
 
m
 
M
each, and 2.5 U of Taq DNA polymerase (Promega Corp., Mad-
ison, WI). Amplification consisted of one cycle at 95
 
8
 
C for 5 min
followed by 40 cycles of 95
 
8
 
C for 45
 
 
 
s, 58
 
8
 
C for 60 s, and 72
 
8
 
C
for 90 s, followed by an extension cycle of 72
 
8
 
C for 5 min. PCR
amplification products were gel purified and cloned into pCR 2.1
(TA cloning kit; Clontech, Palo Alto, CA) according to the man-
ufacturer’s protocol. All inserts were completely sequenced, and
no differences from the published sequence were found. The iso-
lated PCR fragments were then cloned in-frame with a hemag-
glutinin (HA) tag into pcDNA-HA (19) using the NheI and NotI
unique restriction sites.
 
p73 Transcript Analysis.
 
To detect expression, all four p73
splicing variants were amplified by radioactive RT-PCR using
the following primers: 5
 
9
 
-TTCTGCAGGTGACTCAGGCTG-
3
 
9
 
 for RT; and 5
 
9
 
-ACTTTGAGATCCTGATGAAG-3
 
9
 
 (sense
primer) and 5
 
9
 
-CAGATGGTCATGCGGTACTG-3
 
9
 
 (antisense
primer) for PCR amplification. cDNA synthesis was performed as
described above, starting with equal RNA concentrations (1 
 
m
 
g).
Radioactive PCR reaction was performed in 50 
 
m
 
l of reaction
buffer containing 5 
 
m
 
l of the RT product, 50 mM KCl, 10 mM
Tris-HCl (pH 9.0), 0.1% Triton X-100, 1.5 mM MgCl
 
2
 
, dNTPs
0.2 mM each, cold primers 0.4 
 
m
 
M each, plus 40 nM each of
[
 
g
 
-
 
33
 
P]dATP-labeled primers and 2.5 U of Taq DNA polymerase
(Promega Corp.). Amplification consisted of one cycle at 95
 
8
 
C
for 5 min followed by 35 cycles of 95
 
8
 
C for 60 s, 59
 
8
 
C for 55 s,
and 72
 
8
 
C for 45 s. PCR products were separated on a nondena-
turing 6% polyacrylamide gel, dried, and analyzed by autoradiog-
raphy. p53 and GAPDH were amplified using the same protocol
as for p73 with the following primers: for p53, 5
 
9
 
-GAC-
CATCGCTATCTGAGCAGCG-3
 
9
 
 for RT, and 5
 
9
 
-TGCTTT-
CCACGACGGTGACACG-3
 
9
 
 (sense primer) and 5
 
9
 
-GACT-
GCTTGTAGATGGCCATGG (antisense primer) for PCR
amplification; for GAPDH, 5
 
9
 
-TGAAGGTCGGAGTCAACG-
GATTG-3
 
9
 
 (sense primer) and 5
 
9
 
-GCCATGGAATTTGCCA-
TGCCATGGGTGG (antisense primer) for PCR amplification
and RT.
 
Tissue Culture.
 
All of the cell lines were grown in a 1:1 mix-
ture of MEM and Ham’s F-12 medium supplemented with 10%
heat-inactivated FCS, 1.2 g bicarbonate/l, 1% nonessential amino
acids, and 15 mM 
 
N
 
-2-hydroxyethylpiperazine-
 
N
 
9
 
-2-ethane-
sulfonic acid, at 37
 
8
 
C
 
 
 
in a humidified atmosphere of 5% CO
 
2 
 
in
air. SAOS-2 cells were grown in DMEM supplemented with
10% fetal bovine serum.
 
Lymphocyte Analysis.
 
PBLs were purified on a Ficoll gradient,
labeled by direct immunofluorescence with anti-CD4–PE and
anti-CD8–FITC mAbs (Becton Dickinson, San Jose, CA), and
sorted by flow cytometry in a FACSCalibur
 
Ò
 
 (Becton Dickinson)
according to the manufacturer’s protocol. Analysis of the purified
population showed a purity of 97%.
 
Yeast Two-hybrid System.
 
Nucleotide sequences correspond-
ing to amino acids 72–393 of p53, 85–636 of p73
 
a
 
, 85–499 of
p73
 
b
 
, 85–475 of p73g, and 85–403 of p73d were PCR amplified
from the corresponding cDNAs and cloned in-frame into the
Gal4 DNA-binding domain vector pGBT9 (Clontech) and into
the Gal4 transcriptional activation domain pGAD424 (Clontech).
Transformations into the yeast strain SFY526, containing a b-galac-
tosidase encoding gene under the control of GAL1 promoter,
were performed as described (Matchmaker two-hybrid system
protocol; Clontech). b-Gal production was quantified with the
liquid assay described in the Matchmaker two-hybrid system pro-
tocol (Clontech).
Luciferase Assay. SAOS-2 cells were transfected by the calcium
phosphate method with reporter plasmid containing luciferase
cDNA under the control of the p21Waf1/Cip1 promoter, together
with p53 or p73s expression vectors. 48 h after transfection, cells
were lysed and luciferase activity was quantified as described (20).
Growth Suppression Assay. SAOS-2 cells were transfected in
100-mm plates with the indicated pcDNA3-derived vectors using
the calcium phosphate method. 48 h later, cells were placed un-
der G418 (GIBCO BRL) selection (700 mg/ml). After 2 wk,
cells were fixed, stained with crystal violet, and photographed, as
described (21).
Western Blot Analysis. SAOS-2 cells were transfected using
the calcium phosphate method and lysed 48 h later in 50 mM
Tris, pH 8.0, 150 mM NaCl, 0.5% NP-40, 0.5 mg/ml leupeptin,
1 mg/ml aprotinin, and 0.5 mM PMSF. The lysate was cleared by
centrifugation, and 30 mg aliquots of cell extract, as determined
by the Bradford method, were resolved by electrophoresis in a
10% SDS-polyacrylamide gel, transferred to a nylon membrane,
and probed with an anti-HA antibody (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA). Immunocomplexes were detected by
a chemiluminescence-based system (Amersham Pharmacia Bio-
tech, Inc., Piscataway, NJ) according to the manufacturer’s in-
structions.
Results and Discussion
Identification of Two New Splice Variants of p73. The p53
tumor suppressor gene encodes for a phosphorylated pro-
tein, 393 amino acids long and highly conserved throughout
evolution (22). At the structural level, the four functional
domains (1, 2, 23) include the transcriptional activation do-
main (residues 1–42), the DNA-binding domain (residues
102–292), which is the region most frequently mutated in1765 De Laurenzi et al. Brief Definitive Report
cancer, the oligomerization domain (residues 324–355),
and the COOH terminus domain that allosterically regulates
the binding of the central region to DNA. The NH2-termi-
nal transcriptional activation domain binds the members of
the CBP/p300 family of transcriptional adaptors/coactiva-
tors, which are recruited for most p53 biological responses
(24–26). p73 homology to p53 is very high in the transacti-
vation domain (29% identity), in the DNA-binding domain
(63%), and in the oligomerization domain (38% [5]).
p73 gene encodes two distinct polypeptides, p73a and
p73b. The latter arises from the alternative splicing of exon
13 in the p73 transcript (5). With the exception of the last
five residues which are unique to the shorter p73b, the rest
of the protein is identical to the corresponding regions in
p73a. To evaluate whether these splicing variants might
be differentially expressed in different tissues or cell lines,
we systematically characterized p73 transcripts using RT-
PCR. While amplifying the 39 end of the p73 mRNA
from the SH-Sy5y neuroblastoma cell line, we identified
two amplification products of 386 and 154 bp, in addition
to the expected 535- and 440-bp bands, deriving from the
p73a and p73b transcripts, respectively. We cloned and se-
quenced all cDNAs, and found that they corresponded to
four different splice variants of the gene (Fig. 1 A). We
named the two new forms p73g and p73d. p73g mRNA
was generated by splicing of exon 11, whereas p73d tran-
script lacked exons 11, 12, and 13. The splicing of exon 11
in p73g resulted in a frame shift from the original reading
frame leading to the translation of 76 amino acids, different
from the original sequence (from amino acid residue 400 to
residue 475), followed by a premature stop codon (Fig. 1
B). This 76 amino acid sequence did not show any signifi-
cant similarity to other known peptide sequences in the da-
tabase. The resulting p73g protein is 161 amino acids
shorter than the p73a and 24 amino acids shorter than the
p73b form, bearing a new COOH terminus that is differ-
ent from both previously described forms. The splicing of
exons 11, 12, and 13 in p73d resulted in a shorter truncated
form of p73 of 403 amino acids (Fig. 1, A and B). p73d
bears the most striking resemblance to p53, as it completely
lacks the COOH terminus extension that differentiates the
other forms of p73. However, both p73g and p73d still
contain the regions homologous to the transcription activa-
tion domain, the CBP/p300 coactivator binding domain,
and the DNA-binding and oligomerization domains of p53.
Expression Pattern of p73 Splicing Variants. The relative
expression of the p73 isoforms in normal and neoplastic
cells was examined using a radioactive PCR that amplifies
exons 10–14 in the p73 mRNA (bp 1198–1735 of the full-
length mRNA). This strategy identified four bands of 535
(p73a), 440 (p73b), 386 (p73g), and 154 bp (p73d), thus
distinguishing all four splicing variants with a single PCR.
Fig. 2 A shows the results obtained in human PBLs, pri-
mary keratinocytes, eight neuroblastoma cell lines, and
seven other tumor cell lines, including glioblastoma, mela-
noma, hepatoma, and leukemia. Fig. 2 B shows the linear-
ity of the PCR reaction in the same experimental condi-
Figure 1. (A) Schematic representation of p73 splicing isoforms.
Spliced-out exons are indicated with respect to the full-length form,
p73a. (B) Amino acid alignment of the COOH-terminal region of the
four p73 splice variants and comparison with p53. The corresponding ex-
ons are indicated.
Figure 2. (A) Differential expression of p73 splicing variants and p53 in
normal human (PBLs and skin keratinocytes) and cancer cells. Autorad-
iography of a radioactive PCR performed on several neuroblastoma
[BE(2)-M17, SH-Sy5y, BE(2)-2C, SH-EPI, SK-N-BE(2), SMS-KCNR,
CHP100, SH-N-SH, and LAN5], glioblastoma (Lipari), lymphoma (Hut
78, Jurkat), hepatoma (Hep-G2), and breast carcinoma (MCF-7) cell
lines. The four p73 splice variants (p73a: 535 bp; p73b: 440 bp; p73g:
386 bp, and p73d: 154 bp) and the expression of a control housekeeping
gene (GAPDH, bottom lane) are shown. (B) Radioactive PCR for p73,
p53, and GAPDH performed on mRNA extracted from the BE(2)-M17
cell line for 25, 30, and 35 cycles of amplification, showing the linearity of
the reaction. (C) p73 and p53 expression pattern of CD41 and CD81 en-
riched lymphocyte populations sorted by flow cytometry (see Materials
and Methods for details on oligonucleotides and PCR cycles). Radioac-
tive PCR gels shown in the three panels were exposed for 12 h; GAPDH
was exposed for only 2 h.1766 p73 g and d Splice Variants
tions used to amplify p73 and p53. The expression pattern
of the four p73 splicing variants differs both in primary cells
of different lineage and in established cell lines even within
the same type of tumor. Two cell lines, Jurkat lymphoma
and SMS-KCNR neuroblastoma, were completely nega-
tive for p73 expression using our highly sensitive radioac-
tive PCR. Interestingly, normal human lymphocytes lacked
p73b and expressed only the p73a, p73g, and p73d forms,
whereas normal human keratinocytes from a skin biopsy
expressed p73a, p73b, and p73g but not p73d. When
CD41 and CD81 enriched lymphocyte populations (97%
enrichment after flow cytometry cell sorting) were ana-
lyzed, we found that the different forms of p73 were selec-
tively expressed (Fig. 2 C). These results indicate that, al-
though a larger panel of normal tissues needs to be
analyzed, the newly identified p73g and p73d forms are in-
deed expressed in normal primary cells and do not repre-
sent abnormal transcripts expressed only in transformed cell
lines. Our findings also suggest that the various p73 iso-
forms may play distinct roles in cells of different lineage or
at different differentiation stages within the same lineage.
Homotypic and Heterotypic Interactions of p73g and p73d
Isoforms. To study homotypic and heterotypic interac-
tions between the p73g and p73d and both the other p73
isoforms and p53, we used the yeast two-hybrid system
(Fig. 3 A). As reported previously (5), both the a and b
forms interact weakly with p53, whereas the g and d forms
show no interaction with p53. The different forms of p73
interact with each other with variable intensity. p73g
showed strong interactions with all p73 isoforms, including
itself. The interaction with p73b was the strongest. p73d
homodimerizes efficiently and binds p73a and p73g. The
interaction of p73d with the b isoform is much weaker
than that of p73g. We also confirmed that p73a has a very
low tendency to form homotypic interactions, whereas
p73b homodimerizes strongly and binds weakly to p73a.
Comparable results were obtained using the different p73
isoforms in either bait or prey configuration in the two-
hybrid assay. Altogether, these results indicate that all ho-
motypic and several heterotypic interactions are possible
between the p73 variants, and suggest that the same may
occur in vivo to fine-tune the system.
Functional Characterization of p73g and p73d. p73a and
p73b have been previously shown to share with p53 the
ability to activate the transcription of common target regu-
latory sequences (13) and to increase the expression of the
p21Waf1/Cip1 gene (5). To assess whether the two new splic-
ing variants of p73 we identified are also transcriptionally
active, we tested their ability to transactivate the p21Waf1/Cip1
promoter–driven luciferase reporter in the osteogenic sar-
coma cell line SAOS-2, which harbors a homozygous dele-
tion of the p53 gene and does not synthesize p53. The
results shown in Fig. 3 B demonstrate that p73g is signifi-
cantly less efficient in activating transcription from the
p21Waf1/Cip1 promoter than p53 or p73b, whereas the effect
of p73d is intermediate and comparable to that of p73a.
The above-described differences are not due to variations
in the protein levels of the exogenously expressed p73 vari-
ants, as shown in Fig. 3 C. Coexpression of either p73a or
p73d with p73b results in a decrease of p21Waf1/Cip1 pro-
moter activation compared with p73b alone. Interestingly,
p73g, which activates transcription poorly by itself and in-
teracts strongly with p73b, exerts no inhibitory effect. The
molecular basis for these observations is still unclear. In fact,
it remains to be established whether the various p73 ho-
modimers and heterodimers have different DNA-binding
capacity, intrinsic transcription activation activity, or ability
to recruit the transcriptional adaptors/coactivators of the
CBP/p300 family. In keeping with their ability to increase
p21Waf1/Cip1 levels in the cell, both p73a and p73b can in-
duce growth arrest when transfected into SK-N-AS (5) or
SAOS-2 cells (13). We then tested the effect of exogenously
expressed p73g and p73d on cell growth in SAOS-2 cells
using a standard colony formation assay. To this aim, cells
were transfected with the expression vectors either for each
p73 isoform or for p53. After G418 selection for 2 wk,
drug-resistant colonies were stained and counted. The abil-
ity of the different p73 variants to affect cell growth in p53
null SAOS cells correlates well with their transcriptional
activity on the p21Waf1/Cip1 promoter. p73b was the most
efficient in inhibiting colony formation, and p73g was al-
most ineffective (Fig. 4).
In conclusion, we have identified and functionally char-
acterized two new p73 splicing variants named p73g and
Figure 3. (A) Yeast two-hybrid interaction assays among p53, p73a, p73b, p73g, and p73d presented as ordinate values relative to b-galactosidase ac-
tivity of p53–p53 interaction. Control interactions using pGAD or pGBT vectors were negative. (B) Luciferase assay of SAOS-2 cells transfected with
p21Waf1/Cip1 promoter–driven luciferase reporter plasmid (4 mg), together with p53 (20 ng) or p73 (20 ng) expression plasmids. When transfected in com-
bination with each other, 10 ng of each indicated expression plasmid was used. (C) Expression of p73 splicing variants. Anti-HA Western blot of whole
cell extracts after transfection of SAOS-2 cells with plasmids encoding the indicated proteins. Molecular masses are shown in kD (right).1767 De Laurenzi et al. Brief Definitive Report
p73d. Both variants are expressed in human normal cells as
well as in tumor cell lines of different origin. Three lines of
evidence indicate that the p73 system by itself is likely to
provide a complex regulatory mechanism devoted to the
control of cell growth: (a) the finding of different expres-
sion patterns of the four p73 splicing variants in normal and
neoplastic cells; (b) the network of homodimeric and het-
erodimeric interactions of the various p73 isoforms and
p53; and (c) the differences in their transcriptional profi-
ciency and cell growth arrest capacity. The selective ability
of the p73 variants to interact with and possibly to modu-
late the functions of p53 suggests an even more compli-
cated scenario. Indeed, despite the numerous structural and
functional similarities between p73 and p53, we do not yet
know which stimuli regulate the activity of the various p73
isoforms and their relative ratios in the cell. Unlike p53,
which is usually present in small amounts in normal cells
(22, 27) and is induced by DNA-damaging agents and radi-
ation (28), p73 is not upregulated in response to DNA
damage. Although further investigation is necessary to de-
termine how p73 isoforms are activated and/or regulated,
their biological effects may well include cell growth arrest
and possibly the induction of cell death.
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